KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Deferred Revenue (2016 - 2023)

Halozyme Therapeutics (HALO) has disclosed Current Deferred Revenue for 14 consecutive years, with $667000.0 as the latest value for Q3 2023.

  • Quarterly Current Deferred Revenue fell 81.4% to $667000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $667000.0 through Sep 2023, down 81.4% year-over-year, with the annual reading at $3.2 million for FY2022, 24.09% down from the prior year.
  • Current Deferred Revenue for Q3 2023 was $667000.0 at Halozyme Therapeutics, down from $3.1 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $6.9 million in Q2 2022, with the low at $667000.0 in Q3 2023.
  • Average Current Deferred Revenue over 5 years is $3.4 million, with a median of $3.2 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue tumbled 89.85% in 2019, then surged 604.95% in 2021.
  • Over 5 years, Current Deferred Revenue stood at $5.3 million in 2019, then plummeted by 66.8% to $1.7 million in 2020, then soared by 144.9% to $4.3 million in 2021, then fell by 24.09% to $3.2 million in 2022, then plummeted by 79.45% to $667000.0 in 2023.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $667000.0, $3.1 million, and $3.2 million for Q3 2023, Q2 2023, and Q1 2023 respectively.